Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views.


Journal

Joint bone spine
ISSN: 1778-7254
Titre abrégé: Joint Bone Spine
Pays: France
ID NLM: 100938016

Informations de publication

Date de publication:
Nov 2019
Historique:
accepted: 13 12 2018
pubmed: 4 2 2019
medline: 24 6 2020
entrez: 4 2 2019
Statut: ppublish

Résumé

Corneal and scleral disorders related to inflammatory rheumatic diseases vary both in frequency and in severity. Sicca syndrome and its complications are the most common ocular manifestations and, together with episcleritis, can usually be managed by topical treatments. In contrast, the various forms of scleritis and peripheral ulcerative keratitis generally require systemic glucocorticoid therapy and the initiation or intensification of immunosuppressive treatment. Corneal and scleral manifestations are inaugural in a few patients with chronic inflammatory rheumatic disease. No direct information is available on the frequency of severe corneal and scleral involvement, which can only be estimated by extrapolating data from case-series or cohorts, many of which are historical. Similarly, given the absence of randomized controlled trials, treatment decisions must rely on clinical experience acquired in referral centers and on reports of small case-series studies. The rheumatologist and ophthalmologist must work closely together to ensure the prompt and optimal management of these potentially serious conditions.

Identifiants

pubmed: 30711694
pii: S1297-319X(19)30012-0
doi: 10.1016/j.jbspin.2019.01.014
pii:
doi:

Substances chimiques

Glucocorticoids 0
Immunosuppressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

699-705

Informations de copyright

Copyright © 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Gaëlle Clavel (G)

Service de Médecine Interne, Fondation A. de Rothschild, 25-29, rue Manin, 75019 Paris, France; Inserm UMR 1125, 1, rue de Chablis, 93017 Bobigny, France. Electronic address: gaelle.clavel@gmail.com.

Eric Gabison (E)

Service d'ophtalmologie, Fondation A. de Rothschild, 25-29, rue Manin, 75019 Paris, France.

Luca Semerano (L)

Inserm UMR 1125, 1, rue de Chablis, 93017 Bobigny, France; Service de rhumatologie, assistance publique-Hôpitaux de Paris (AP-HP), groupe hospitalier Avicenne Jean-Verdier-René-Muret, 125, rue de Stalingrad, 93017 Bobigny, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH